---
title: "UBS Reaffirms Their Hold Rating on Medartis Holding AG (MED)"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/279632894.md"
description: "UBS analyst Tanya Hansalik has reaffirmed a Hold rating on Medartis Holding AG (MED) with a price target of CHF92.00. The analyst focuses on the Healthcare sector and has an average return of -7.3% with an 18.18% success rate on stock recommendations. The consensus among analysts for Medartis Holding AG is also a Hold, with a price target of CHF92.00."
datetime: "2026-03-18T12:55:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279632894.md)
  - [en](https://longbridge.com/en/news/279632894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279632894.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/279632894.md) | [English](https://longbridge.com/en/news/279632894.md)


# UBS Reaffirms Their Hold Rating on Medartis Holding AG (MED)

In a report released today, Tanya Hansalik from UBS maintained a Hold rating on Medartis Holding AG, with a price target of CHF92.00.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Hansalik covers the Healthcare sector, focusing on stocks such as Siegfried Holding AG, PolyPeptide Group AG, and Medartis Holding AG. According to TipRanks, Hansalik has an average return of \-7.3% and a 18.18% success rate on recommended stocks.

Medartis Holding AG has an analyst consensus of Hold, with a price target consensus of CHF92.00.

### 相關股票

- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Proshares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/zh-HK/quote/BIS.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)

## 相關資訊與研究

- [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/zh-HK/news/281544776.md)
- [07:03 ETSobi publishes Annual and Sustainability Report for 2025](https://longbridge.com/zh-HK/news/281174129.md)
- [02:10 ETAbbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children](https://longbridge.com/zh-HK/news/281132830.md)
- [09:00 ETDelonix Bioworks Announces Initiation of Phase 1 First-in-Human Clinical Trial of a Next-Generation MenB OMV Vaccine DX-104](https://longbridge.com/zh-HK/news/281025352.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/zh-HK/news/281644038.md)